Published in Ann Intern Med on May 20, 2003
Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68
Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum (2010) 1.63
TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev (2011) 1.47
Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis (2005) 1.36
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis (2005) 1.19
Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol (2009) 1.19
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis (2004) 1.14
What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis (2007) 1.09
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol (2009) 1.06
Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res (2015) 1.05
Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther (2009) 1.01
Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) (2007) 0.99
Biologics in inflammatory bowel disease: how much progress have we made? Gut (2004) 0.99
Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol (2007) 0.91
Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol (2014) 0.90
Gut health immunomodulatory and anti-inflammatory functions of gut enzyme digested high protein micro-nutrient dietary supplement-Enprocal. BMC Immunol (2009) 0.90
Clinicians' guide to statistics for medical practice and research: part I. Ochsner J (2006) 0.89
Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr (2004) 0.86
Adalimumab for the treatment of Crohn's disease. Biologics (2008) 0.86
The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int (2006) 0.85
The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol (2013) 0.85
Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol (2013) 0.85
Treatment of severe psoriasis with infliximab. Ther Clin Risk Manag (2008) 0.82
The scientific establishment of a new therapeutic intervention for developmental conditions: practical and ethical principles. Childs Nerv Syst (2003) 0.80
Advances in targeted therapy: safety of biological agents. Ann Rheum Dis (2003) 0.80
Infliximab for the treatment of plaque psoriasis. Biologics (2008) 0.79
Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis. BMJ Case Rep (2014) 0.79
Two evils: gastrocolic fistula and heart failure. Dig Dis Sci (2013) 0.79
Effective Strategies for the Management of Pyoderma Gangrenosum. Adv Wound Care (New Rochelle) (2012) 0.78
Prolonged QT dispersion in inflammatory bowel disease. World J Gastroenterol (2013) 0.78
Potential role of ustekinumab in the treatment of chronic plaque psoriasis. Biologics (2010) 0.78
Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol (2008) 0.77
The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag (2007) 0.76
Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol (2010) 0.76
Innate immune receptors in heart failure: Side effect or potential therapeutic target? World J Cardiol (2014) 0.75
A practical approach to monitoring patients on biological agents for the treatment of psoriasis. J Clin Aesthet Dermatol (2010) 0.75
A practical approach to screening psoriasis patients for therapy with biologic agents. J Clin Aesthet Dermatol (2008) 0.75
Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers. Ann Rheum Dis (2004) 0.75
Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol (2008) 0.75
[TNFalpha inhibitors in the treatment of uveitis]. Ophthalmologe (2005) 0.75
Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Dig Dis Sci (2017) 0.75
[Biologics and cardiovascular risk]. Z Rheumatol (2010) 0.75
Arterial stiffness is associated with left ventricular dysfunction in patients with rheumatoid arthritis. Clin Rheumatol (2016) 0.75
Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Clin Rheumatol (2012) 0.75
Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA (2009) 13.69
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA (2012) 6.56
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA (2009) 5.58
What clinicians should know about the QT interval. JAMA (2003) 4.45
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation (2006) 3.96
Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer (2002) 3.89
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 3.63
Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med (2009) 3.60
Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care (2007) 3.53
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA (2006) 3.41
Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol (2004) 2.79
Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol (2010) 2.68
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis (2004) 2.68
Autologous cultured chondrocytes: adverse events reported to the United States Food and Drug Administration. J Bone Joint Surg Am (2006) 2.50
SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol (2002) 2.13
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum (2002) 2.12
Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J (2007) 2.12
Monitoring the quality of conduct of clinical trials: a survey of current practices. Clin Trials (2011) 2.08
Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov (2010) 2.05
Risk stratification after hospitalization for decompensated heart failure. J Card Fail (2004) 2.04
Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics (2002) 1.98
Tissues from population-based cancer registries: a novel approach to increasing research potential. Hum Pathol (2005) 1.92
Pathology and classification of ovarian tumors. Cancer (2003) 1.90
Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol (2004) 1.89
Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med (2008) 1.88
Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA (2005) 1.84
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol (2005) 1.82
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J (2004) 1.76
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. J Card Fail (2006) 1.72
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. MMWR Surveill Summ (2003) 1.70
Adverse event reports following yellow fever vaccination. Vaccine (2008) 1.63
Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics (2008) 1.63
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum (2003) 1.58
Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation (2004) 1.55
Spending on postapproval drug safety. Health Aff (Millwood) (2006) 1.50
Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Vaccine (2008) 1.48
Multifaceted intervention to promote beta-blocker use in heart failure. Am Heart J (2006) 1.48
Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf (2012) 1.46
Using central IRBs for multicenter clinical trials in the United States. PLoS One (2013) 1.43
Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med (2008) 1.42
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol (2003) 1.41
Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol (2003) 1.40
On the hazard ratios and corresponding confidence intervals that appear in Basran et al. (2006). Anesth Analg (2007) 1.39
Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol (2002) 1.38
Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol (2003) 1.27
Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol (2011) 1.21
Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J (2008) 1.18
Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discov Today (2010) 1.18
Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform (2011) 1.17
The need for worldwide policy and action plans for rare diseases. Acta Paediatr (2012) 1.13
Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf (2005) 1.10
Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature. Clin Trials (2013) 1.09
A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med (2008) 1.09
A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. Pharmacoepidemiol Drug Saf (2008) 1.09
Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J (2012) 1.06
The association between depression and chronic kidney disease and mortality among patients hospitalized with congestive heart failure. Am J Kidney Dis (2004) 1.06
Orphan products: an emerging trend in drug approvals. Nat Rev Drug Discov (2010) 1.04
Association of depression and survival in patients with chronic heart failure over 12 Years. Psychosomatics (2012) 0.99
Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet (2002) 0.96
Duchenne muscular dystrophy: Drug development and regulatory considerations. Muscle Nerve (2010) 0.95
Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine (2006) 0.95
Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med (2002) 0.95
Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail (2002) 0.95
Therapies for inborn errors of metabolism: what has the orphan drug act delivered? Pediatrics (2010) 0.94
Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf (2006) 0.94
Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov (2011) 0.94
Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine (2007) 0.94
Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans. Pharmacoepidemiol Drug Saf (2008) 0.93
Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA (2004) 0.92
Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics (2005) 0.91
Part I: Identifying holes in the safety net. Am Heart J (2004) 0.91
Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr Infect Dis J (2009) 0.90
Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). Drug Saf (2008) 0.90
Postmarket evaluation of breakthrough technologies. Am Heart J (2008) 0.90
Variations in coronary procedure utilization depending on body mass index. Arch Intern Med (2005) 0.89
Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf (2007) 0.89
Part II: Sealing holes in the safety net. Am Heart J (2004) 0.89
What should an ideal vaccine postlicensure safety system be? Am J Public Health (2009) 0.89
An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone? Pediatrics (2004) 0.88
Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol (2003) 0.88
Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. Am J Cardiol (2003) 0.88
The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine (2007) 0.88
Knowledge deficits related to the QT interval could affect patient safety. Ann Noninvasive Electrocardiol (2003) 0.87
Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol (2002) 0.87
Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine (2002) 0.86
Active influenza vaccine safety surveillance: potential within a healthcare claims environment. Med Care (2009) 0.86
A survey of health care practitioners' knowledge of the QT interval. J Gen Intern Med (2005) 0.86
Long-term clinical outcomes following coronary stenting. Arch Intern Med (2008) 0.85
Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System. J Clin Epidemiol (2002) 0.85
Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis (2003) 0.83
HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum (2009) 0.83
Evaluation of Guillain-Barré Syndrome among recipients of influenza vaccine in 2000 and 2001. Am J Prev Med (2010) 0.83